158 related articles for article (PubMed ID: 34108648)
1. Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function.
Joyce DD; Wallis CJD; Luckenbaugh AN; Huelster HL; Zhao Z; Hoffman KE; Huang LC; Koyama T; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; Neil BBO; Kaplan SH; Greenfield S; Penson DF; Barocas DA
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):238-247. PubMed ID: 34108648
[TBL] [Abstract][Full Text] [Related]
2. Potency preservation following stereotactic body radiation therapy for prostate cancer.
Obayomi-Davies O; Chen LN; Bhagat A; Wright HC; Uhm S; Kim JS; Yung TM; Lei S; Batipps GP; Pahira J; McGeagh KG; Collins BT; Kowalczyk K; Bandi G; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Nov; 8():256. PubMed ID: 24180317
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
Teloken PE; Ohebshalom M; Mohideen N; Mulhall JP
J Urol; 2007 Dec; 178(6):2521-5. PubMed ID: 17937948
[TBL] [Abstract][Full Text] [Related]
4. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
Royce TJ; Chen MH; Wu J; Loffredo M; Renshaw AA; Kantoff PW; D'Amico AV
JAMA Oncol; 2017 May; 3(5):652-658. PubMed ID: 28097317
[TBL] [Abstract][Full Text] [Related]
5. Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
Lee W; Lim B; Kyung YS; Kim CS
Int J Urol; 2022 May; 29(5):414-420. PubMed ID: 35133691
[TBL] [Abstract][Full Text] [Related]
6. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
7. Sexual Motivators and Endorsement of Models Describing Sexual Response of Men Undergoing Androgen Deprivation Therapy for Advanced Prostate Cancer.
Fode M; Mosholt KS; Nielsen TK; Tolouee S; Giraldi A; Østergren PB; Azawi N
J Sex Med; 2020 Aug; 17(8):1538-1543. PubMed ID: 32448679
[TBL] [Abstract][Full Text] [Related]
8. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
9. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
Gay HA; Sanda MG; Liu J; Wu N; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal CS; Litwin MS; Kuban DA; Hembroff L; Regan MM; Chang P; ; Michalski JM
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):304-317. PubMed ID: 28463150
[TBL] [Abstract][Full Text] [Related]
10. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.
Koontz BF; Hoffman KE; Halabi S; Healy P; Anand M; George DJ; Harrison MR; Zhang T; Berry WR; Corn PG; Lee WR; Armstrong AJ
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1271-1278. PubMed ID: 33259932
[TBL] [Abstract][Full Text] [Related]
11. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
Ng E; Woo HH; Turner S; Leong E; Jackson M; Spry N
J Urol; 2012 Jun; 187(6):2162-6. PubMed ID: 22503022
[TBL] [Abstract][Full Text] [Related]
12. Sexual Function After Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: Results From the Randomized Phase III HYPRO Trial.
Wortel RC; Pos FJ; Heemsbergen WD; Incrocci L
J Sex Med; 2016 Nov; 13(11):1695-1703. PubMed ID: 27665195
[TBL] [Abstract][Full Text] [Related]
13. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
14. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
15. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
[TBL] [Abstract][Full Text] [Related]
16. Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Wilt TJ; Ullman KE; Linskens EJ; MacDonald R; Brasure M; Ester E; Nelson VA; Saha J; Sultan S; Dahm P
J Urol; 2021 Apr; 205(4):967-976. PubMed ID: 33350857
[TBL] [Abstract][Full Text] [Related]
17. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.
Tsai HT; Keating NL; Van Den Eeden SK; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Smith MR; Potosky AL
J Urol; 2015 Jun; 193(6):1956-62. PubMed ID: 25524243
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Jones CU; Hunt D; McGowan DG; Amin MB; Chetner MP; Bruner DW; Leibenhaut MH; Husain SM; Rotman M; Souhami L; Sandler HM; Shipley WU
N Engl J Med; 2011 Jul; 365(2):107-18. PubMed ID: 21751904
[TBL] [Abstract][Full Text] [Related]
19. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
[TBL] [Abstract][Full Text] [Related]
20. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
Cooperberg MR; Vickers AJ; Broering JM; Carroll PR
Cancer; 2010 Nov; 116(22):5226-34. PubMed ID: 20690197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]